SETH LERNER to Tumor Suppressor Protein p53
This is a "connection" page, showing publications SETH LERNER has written about Tumor Suppressor Protein p53.
Connection Strength
0.852
-
p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol. 2004 Mar 15; 22(6):1014-24.
Score: 0.165
-
Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology. 2003 Jun; 61(6):1140-5.
Score: 0.157
-
Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens. Int J Radiat Oncol Biol Phys. 2001 Sep 01; 51(1):16-22.
Score: 0.139
-
SIU-ICUD consultation on bladder cancer: basic science. World J Urol. 2019 Jan; 37(1):15-29.
Score: 0.115
-
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol. 2011 Sep 01; 29(25):3443-9.
Score: 0.069
-
p53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU Int. 2010 Feb; 105(4):489-95.
Score: 0.060
-
Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer. Urology. 2005 Aug; 66(2):441-6.
Score: 0.046
-
Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J Urol. 2003 Mar; 169(3):938-42.
Score: 0.039
-
Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology. 2000 Nov 01; 56(5):735-40.
Score: 0.033
-
Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol. 2010 Jan; 183(1):68-75.
Score: 0.015
-
Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer. 2008 Jan 15; 112(2):315-25.
Score: 0.014